A detailed history of China Universal Asset Management Co., Ltd. transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 15,594 shares of RLAY stock, worth $101,205. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,594
Previous 25,210 38.14%
Holding current value
$101,205
Previous $209,000 51.67%
% of portfolio
0.01%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$5.9 - $8.02 $56,734 - $77,120
-9,616 Reduced 38.14%
15,594 $101,000
Q1 2024

Apr 29, 2024

BUY
$7.5 - $12.07 $82,147 - $132,202
10,953 Added 76.83%
25,210 $209,000
Q4 2023

May 21, 2024

SELL
$6.01 - $11.48 $65,827 - $125,740
-10,953 Reduced 43.45%
14,257 $156,000
Q4 2023

Jan 23, 2024

BUY
$6.01 - $11.48 $66,843 - $127,680
11,122 Added 354.77%
14,257 $157,000
Q3 2023

May 21, 2024

BUY
$8.24 - $12.97 $12,697 - $19,986
1,541 Added 96.68%
3,135 $26,000
Q3 2023

Oct 30, 2023

BUY
$8.24 - $12.97 $12,697 - $19,986
1,541 Added 96.68%
3,135 $26,000
Q2 2023

May 21, 2024

SELL
$9.99 - $18.27 $499 - $913
-50 Reduced 3.04%
1,594 $20,000
Q2 2023

Jul 27, 2023

SELL
$9.99 - $18.27 $499 - $913
-50 Reduced 3.04%
1,594 $20,000
Q1 2023

May 21, 2024

BUY
$15.0 - $22.76 $6,240 - $9,468
416 Added 33.88%
1,644 $27,000
Q1 2023

Apr 27, 2023

BUY
$15.0 - $22.76 $6,240 - $9,468
416 Added 33.88%
1,644 $27,000
Q4 2022

May 21, 2024

SELL
$14.16 - $24.02 $339,585 - $576,047
-23,982 Reduced 95.13%
1,228 $18,000
Q4 2022

Jan 31, 2023

BUY
$14.16 - $24.02 $2,945 - $4,996
208 Added 20.39%
1,228 $18,000
Q3 2022

Oct 21, 2022

BUY
$18.07 - $31.37 $18,431 - $31,997
1,020 New
1,020 $23,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $780M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.